Cargando…
Novel agents for chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine...
Autores principales: | Wu, Mei, Akinleye, Akintunde, Zhu, Xiongpeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659027/ https://www.ncbi.nlm.nih.gov/pubmed/23680477 http://dx.doi.org/10.1186/1756-8722-6-36 |
Ejemplares similares
-
Novel agents for advanced pancreatic cancer
por: Akinleye, Akintunde, et al.
Publicado: (2015) -
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
por: Zhu, Xiongpeng, et al.
Publicado: (2010) -
FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018) -
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019) -
Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents
por: Tadmor, Tamar, et al.
Publicado: (2021)